BioMarin Pharmaceutical Inc. Stock News

Following FDA's approval, BioMarin's (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A.

BioMarin Pharmaceutical Inc. BMRN, -3.57% received Food and Drug Administration approval of its gene therapy Roctavian to treat hemophilia A, the agency said late Thursday. The FDA said Roctavian was

The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical's gene therapy for hemophilia A, the company said, giving patients with the inherited bleeding disorder an option to

Andreas Halvorsen (Trades, Portfolio), the chief investment officer of Viking Global Investors, disclosed earlier this week he reduced his stake in Roivant Sciences Ltd. ( ROIV , Financial) by 14.73%.

The biotech sector will always house stocks with explosive upside potential. The very nature of the sector ensures that will continue to be the case.

Navigating the turbulent waters in the biotech space is no mean feat. With the sector's inherent volatility due to testing clinical trials and regulatory hurdles, the road toward market approval can b

When it comes to possibilities of outsized rewards, few sectors can beat out biotech stocks with blockbuster potential. Fundamentally, the underlying sector enjoys a massive footprint.

PTC stock surged Wednesday after the company unveiled promising results for its rare disease treatment, a rival to BioMarin's Kuvan. The post Why PTC Therapeutics Could Be Victorious In Its Rare-Disea

AOMR, BMRN and CUTR have been added to the Zacks Rank #5 (Strong Sell) List on May 1, 2023.

BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.55 per share a year ago.

Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indi

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.

Wall Street and investors tend to be more mindful of valuations during a bear market. Although these high-octane stocks aren't cheap based on the traditional price-to-earnings ratio, their growth rate